Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...
The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on track to be cleared until Tuesday afternoon, a person familiar with the ...
Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), and other vaccine developers extended recent gains on Tuesday as investors reacted to rising flu and COVID-19 cases in the U.S. following the latest ...
After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who ...
How the United States' potential fourth vaccine stacks up against existing ones. Maryland-based biotech company Novavax said Monday that its COVID-19 vaccine was shown to be highly effective in ...
GAITHERSBURG, Md., Oct. 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® to Sanofi, in the European ...
Hosted on MSN
Novavax Wins FDA Approval For COVID-19 Vaccine: Retail Calls For Buyback And Bigger Moves
Novavax Inc. drew retail attention on Friday after receiving a Biologics License Application for its COVID-19 vaccine, Nuvaxovid, from the U.S. Food and Drug Administration. Novavax shares closed at ...
FILE - A vial of the Phase 3 Novavax coronavirus vaccine prepared for use in a trial at St. George's University hospital in London, Oct. 7, 2020. (AP Photo/Alastair Grant, File) WASHINGTON (AP) — ...
NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback